I see that Fast Company named OGXI as one of the "World's 50 Most Innovative Companies" , placing in the Top Ten in Biotechs.
We all know about the pipeline - 011 and 427 which use ASO to target clusterin, the protein that grows cancer. Unsung and carrying great potential is the HSP technology which depicts landscape of protein and cell and allows specific targeting through drugs.
Point of clarification about pipeline and innovation, I think I was excited about recognition.
011 targets clusterin; 427 targets HSP27; both are novel chaperones associated with treatment resistance. they are able to move across changes in shifting disease landscape and more adaptable if change occurs in disease landscape.
OGXI has been very efficient with use of capital resources off of leveraged partnerships. So this illustrates how management, like drug products, is innovative.